Deferred Tax Assets, Valuation Allowance of Allogene Therapeutics, Inc. from 31 Dec 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Allogene Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2018 to 31 Dec 2025.
  • Allogene Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $501,766,000, a 13% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Allogene Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $501,766,000 +$56,978,000 +13% 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q4 2024 $444,788,000 +$45,104,000 +11% 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q4 2023 $399,684,000 +$80,054,000 +25% 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q4 2022 $319,630,000 +$108,173,000 +51% 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q4 2021 $211,457,000 +$28,498,000 +16% 31 Dec 2021 10-K 14 Mar 2024 2023 FY
Q4 2020 $182,959,000 +$91,055,000 +99% 31 Dec 2020 10-K/A 14 Mar 2024 2022 FY
Q4 2019 $91,904,000 +$49,988,000 +119% 31 Dec 2019 10-K 23 Feb 2022 2021 FY
Q4 2018 $41,916,000 31 Dec 2018 10-K 25 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.